234 related articles for article (PubMed ID: 34157669)
1. Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia.
Marquina C; Ademi Z; Zomer E; Ofori-Asenso R; Tate R; Liew D
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105931. PubMed ID: 34157669
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation.
Bajorek B; Gao L; Lillicrap T; Bivard A; Garcia-Esperon C; Parsons M; Spratt N; Holliday E; Levi C
J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105213. PubMed ID: 33066879
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of an Individualised Management Program after Stroke: A Trial-Based Economic Evaluation.
Orman Z; Olaiya MT; Thrift AG; Cadilhac DA; Phan T; Nelson MR; Ung D; Srikanth VK; Bladin CF; Gerraty RP; Phillipos J; Kim J
Neuroepidemiology; 2024; 58(3):156-165. PubMed ID: 38359812
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
5. Societal value of stem cell therapy in stroke--a modeling study.
Svensson J; Ghatnekar O; Lindgren A; Lindvall O; Norrving B; Persson U; Kokaia Z
Cerebrovasc Dis; 2012; 33(6):532-9. PubMed ID: 22571941
[TBL] [Abstract][Full Text] [Related]
6. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
Marklund M; Zheng M; Veerman JL; Wu JHY
PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of Australia's Active After-School Communities program.
Moodie ML; Carter RC; Swinburn BA; Haby MM
Obesity (Silver Spring); 2010 Aug; 18(8):1585-92. PubMed ID: 19893504
[TBL] [Abstract][Full Text] [Related]
8. The economic and health burden of stroke among younger adults in Australia from a societal perspective.
Tan E; Gao L; Collier JM; Ellery F; Dewey HM; Bernhardt J; ; Moodie M
BMC Public Health; 2022 Feb; 22(1):218. PubMed ID: 35114974
[TBL] [Abstract][Full Text] [Related]
9. Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework?
Pandya A; Soeteman DI; Gupta A; Kamel H; Mushlin AI; Rosenthal MB
Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006492. PubMed ID: 32615799
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of mechanical thrombectomy for acute ischemic stroke: an Australian payer perspective.
Arora N; Makino K; Tilden D; Lobotesis K; Mitchell P; Gillespie J
J Med Econ; 2018 Aug; 21(8):799-809. PubMed ID: 29741126
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of the Community Benefit of the Australian Pregnancy Register of Antiseizure Medications.
Ademi Z; Marquina C; Perucca P; Hitchcock A; Graham J; Eadie MJ; Liew D; O'Brien TJ; Vajda FJ
Neurology; 2023 Mar; 100(10):e1028-e1037. PubMed ID: 36460471
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of optimizing acute stroke care services for thrombolysis.
Penaloza-Ramos MC; Sheppard JP; Jowett S; Barton P; Mant J; Quinn T; Mellor RM; Sims D; Sandler D; McManus RJ;
Stroke; 2014 Feb; 45(2):553-62. PubMed ID: 24385272
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
[TBL] [Abstract][Full Text] [Related]
15. Dedicated Perioperative Hip Fracture Comanagement Programs are Cost-effective in High-volume Centers: An Economic Analysis.
Swart E; Vasudeva E; Makhni EC; Macaulay W; Bozic KJ
Clin Orthop Relat Res; 2016 Jan; 474(1):222-33. PubMed ID: 26260393
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
Ademi Z; Pasupathi K; Liew D
Medicine (Baltimore); 2016 May; 95(18):e3531. PubMed ID: 27149456
[TBL] [Abstract][Full Text] [Related]
19. Telemedicine for Stroke: Quantifying the Long-Term National Costs and Health Benefits.
Gao L; Tan E; Kim J; Bladin CF; Dewey HM; Bagot KL; Cadilhac DA; Moodie M
Front Neurol; 2021; 12():804355. PubMed ID: 35813183
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
